Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Comparison of Pre-Treatment Sociodemographic and Clinical Characteristics, Symptoms, and Quality of Life Among Older Patients with AML Who Received Intensive Versus Non-Intensive Therapy

Sara M. Tinsley-Vance, Cecile A. Lengacher, Steve K. Sutton, Ram Thapa, Martine Extermann, Daniel Lastorino, Andrew T. Kuykendall, Timothy Kubal, Eric Padron, Onyee Chan, Alison R. Walker, Areej El-Jawahri, David Sallman, Rami S. Komrokji, Jeffrey E Lancet

Blood (2024) 144 (Supplement 1): 7915.

https://doi.org/10.1182/blood-2024-211823

Published: 2024

Journal Articles

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Jeremy V. DiGennaro, Dimitrios Drekolias, Najla H. Al Ali, Onyee Chan, Seongseok Yun, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, Rami S. Komrokji, David Sallman

Blood (2024) 144 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2024-208927

Published: 2024

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Somedeb Ball, Najla H. Al Ali, Akriti G. Jain, Moazzam Shahzad, Junmin Whiting, Daniel Lastorino, Zhuoer Xie, Alison R. Walker, Onyee Chan, Eric Padron, Jongphil Kim, Jeffrey E Lancet, David Sallman, Sara M. Tinsley-Vance, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 532.

https://doi.org/10.1182/blood-2024-209273

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

Journal Articles

A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Onyee Chan, Kendra L. Sweet, Jhada-Kai Hunter, Somedeb Ball, Qianxing Mo, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Rami S. Komrokji, Jeffrey E Lancet, David Sallman

Blood (2024) 144 (Supplement 1): 1520.

https://doi.org/10.1182/blood-2024-205977

Published: 2024

Journal Articles

Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience

Fatima Tuz Zahra, Faustine Ong, Daniel Walgenbach, Onyee Chan, Katherine Tobon, Jeffrey E Lancet, David Sallman, Rami S. Komrokji, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Zhuoer Xie, Seongseok Yun

Blood (2024) 144 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2024-202576

Published: 2024

Journal Articles

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall, Tania Jain, Abhay Singh, Kristen M. Pettit, Quan Lovette, Joan McFadden Cain, Tracy Ann Cinalli, Mary Gallagher, David Sallman, Qianxing Mo, Ling Zhang, Onyee Chan, Alison R. Walker, Zhuoer Xie, Jeffrey E Lancet, Maria Balasis, Seongseok Yun, Eric Padron, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 481.

https://doi.org/10.1182/blood-2024-210743

Published: 2024

Journal Articles

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Fatima Tuz Zahra, Faustine Ong, Moazzam Shahzad, Onyee Chan, Najla H. Al Ali, Jeffrey E Lancet, Alison R. Walker, David Sallman, Rami S. Komrokji, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie

Blood (2024) 144 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2024-211740

Published: 2024

Journal Articles

CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?

Rami S. Komrokji, Zena Komrokji, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Joseph E. Jabbour, Alison R. Walker, Jeffrey E Lancet, David Sallman, Eric Padron

Blood (2024) 144 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2024-205451

Published: 2024

Journal Articles

Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

Katherine Tobon, Kylie Consalvo, Syeda Saba Kareem, Jeffrey E Lancet, Rami S. Komrokji, Javier Pinilla-Ibarz, David Sallman, Jennifer Eatrides, Alison R. Walker, Julio C. Chavez, Leidy Lismeris Isenalumhe, Bijal D Shah

Blood (2024) 144 (Supplement 1): 2820.

https://doi.org/10.1182/blood-2024-201486

Published: 2024

Journal Articles

Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes

Rami S. Komrokji, Zena Komrokji, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Joseph E. Jabbour, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman

Blood (2024) 144 (Supplement 1): 3217.

https://doi.org/10.1182/blood-2024-205861

Published: 2024

Journal Articles

Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)

David Sallman, Amy F McLemore, Onyee Chan, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie, Alison R. Walker, David H Spencer, Rami S. Komrokji, Jeffrey E Lancet, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2024-205211

Published: 2024

Journal Articles

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Ziad Abuhelwa, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 4589.

https://doi.org/10.1182/blood-2024-204064

Published: 2024

Journal Articles

IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)

Rami S. Komrokji, Najla H. Al Ali, Zhuoer Xie, Zena Komrokji, Joseph E. Jabbour, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman

Blood (2024) 144 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2024-204167

Published: 2024

Journal Articles

Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications

Hammad Tashkandi, Xiaohui Zhang, Rami S. Komrokji, Najla H. Al Ali, Zhuoer Xie, Alison R. Walker, Eric Padron, Jeffrey E Lancet, David Sallman, Ling Zhang

Blood (2024) 144 (Supplement 1): 3227.

https://doi.org/10.1182/blood-2024-211460

Published: 2024

Journal Articles

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Blood (2024) 144 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2024-210599

Published: 2024

Journal Articles

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Jeremy V. DiGennaro, George Concepcion, Najla H. Al Ali, Onyee Chan, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, David Sallman, Ashwin Kishtagari, Pankit Vachhani, John O. Mascarenhas, Rami S. Komrokji, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 4561.

https://doi.org/10.1182/blood-2024-202579

Published: 2024

Journal Articles

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Onyee Chan, Kendra L. Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Ann Nardelli, Jatinder K. Lamba, Jongphil Kim, Jinming Song, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Rami S. Komrokji, Jeffrey E Lancet, David Sallman

Blood (2024) 144 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2024-206161

Published: 2024

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax

Onyee Chan, Luis E. Aguirre, Mary Burke, Najla H Al Ali, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Jeffrey Lancet, Rami S. Komrokji, David A Sallman

Blood (2023) 142 (Supplement 1): 5935.

https://doi.org/10.1182/blood-2023-173637

Published: 2023

NARROW

Comparison of Pre-Treatment Sociodemographic and Clinical Characteristics, Symptoms, and Quality of Life Among Older Patients with AML Who Received Intensive Versus Non-Intensive Therapy

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?

Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes

Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)

Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only